
1. On a GAAP basis, third-quarter Abbott sales increased 23%.
2. Third-quarter GAAP diluted EPS was $1.17.
3. Third-quarter diluted EPS from continuing operations on a GAAP basis reflects 70% growth.
4. Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $3.55 to $3.65. Abbott forecasts specified items for the full-year 2021 of $1.45 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, including expenses to align its COVID-19 testing operations with changes during the year in required and permitted testing demand, expenses associated with acquisition and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $5.00 to $5.10 for full-year 2021.
5. Full-year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of 45% at the mid-point versus the prior year.
6. On a GAAP basis, Diagnostics sales increased 48.2%; Medical Devices sales increased 14.6%; Nutrition sales increased 9.6%; Established Pharmaceuticals sales increased 15.1%.
7. On a GAAP basis, third-quarter Abbott sales, excluding COVID-19 testing-related sales, increased 12% compared to sales in 2019.
8. On a GAAP basis, third-quarter sales for Medical Devices increased 19% compared to sales in 2019.
9. On a GAAP basis, third-quarter sales for Diagnostics, excluding COVID-19 testing-related sales, increased 14%.
10. On a GAAP basis, FreeStyle Libre and Libre Sense increased 42%.
11. The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
12. Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” in its Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to update or revise publicly any forward-looking statements for any reason or for any eventuality.